Sai Life Sciences Ltd.
Sai Life Sciences Ltd. Fundamental Analysis
Sai Life Sciences Ltd. (SAILIFE.NS) shows weak financial fundamentals with a PE ratio of 60.67, profit margin of 15.59%, and ROE of 15.14%. The company generates $21.5B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 49.8/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SAILIFE.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakSAILIFE.NS struggles to generate sufficient returns from assets.
Valuation Score
WeakSAILIFE.NS trades at a premium to fair value.
Growth Score
ModerateSAILIFE.NS shows steady but slowing expansion.
Financial Health Score
ExcellentSAILIFE.NS maintains a strong and stable balance sheet.
Profitability Score
ModerateSAILIFE.NS maintains healthy but balanced margins.
Key Financial Metrics
Is SAILIFE.NS Expensive or Cheap?
P/E Ratio
SAILIFE.NS trades at 60.67 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SAILIFE.NS's PEG of 3.16 indicates potential overvaluation.
Price to Book
The market values Sai Life Sciences Ltd. at 8.90 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 31.02 times EBITDA. This signals the market has high growth expectations.
How Well Does SAILIFE.NS Make Money?
Net Profit Margin
For every $100 in sales, Sai Life Sciences Ltd. keeps $15.59 as profit after all expenses.
Operating Margin
Core operations generate 21.50 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $15.14 in profit for every $100 of shareholder equity.
ROA
Sai Life Sciences Ltd. generates $9.99 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sai Life Sciences Ltd. produces operating cash flow of $3.07B, showing steady but balanced cash generation.
Free Cash Flow
Sai Life Sciences Ltd. generates weak or negative free cash flow of $-1.99B, restricting financial flexibility.
FCF Per Share
Each share generates $-9.40 in free cash annually.
FCF Yield
SAILIFE.NS converts -0.97% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
60.67
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
3.16
vs 25 benchmark
P/B Ratio
Price to book value ratio
8.90
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.52
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.92
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.15
vs 25 benchmark
ROA
Return on assets percentage
0.10
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How SAILIFE.NS Stacks Against Its Sector Peers
| Metric | SAILIFE.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 60.67 | 28.45 | Worse (Expensive) |
| ROE | 15.14% | 763.00% | Weak |
| Net Margin | 15.59% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.25 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.92 | 2795.60 | Neutral |
| ROA | 9.99% | -16588.00% (disorted) | Weak |
SAILIFE.NS outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sai Life Sciences Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation